Riemser is a pan-European specialty pharma company that has strengths in the marketing and distribution of pharmaceuticals in niche areas of oncology, neurology, infectious diseases and other fields.

A fully integrated global biopharma company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients all over the world with a leading position in cancer ...

39-43 Putney High Street, Putney London, SW15 1SP United Kingdom ...

AstraZeneca and Daiichi Sankyo withdraw EU application for datopotamab deruxtecan in NSCLC after Phase III trial shows no ...

Viatris faces US FDA regulatory action on its Indore, India facility, with a warning letter and import alert restricting 11 ...

US pharma major Bristol Myers Squibb has announced positive results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055 ...

The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza ...

The US subsidiary of Japan’s Sumitomo Pharma announced that the US Food and Drug Administration (FDA) has approved Gemtesa ...

USA-based immunology company RAPT Therapeutics has entered into an exclusive license agreement with Shanghai Jemincare ...

USA-based clinical-stage biopharma Traws Pharma saw its shares leap more than 150% to $12.57 as it announced progress in the ...

Cytokinetics (Nasdaq: CYTK) has sold Sanofi (Euronext: SAN) exclusive rights to develop and commercialize aficamten in China.

Poxel is a biopharmaceutical company developing drugs for metabolic diseases, with a focus on type 2 diabetes. Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono. Poxel is focsed on ...